ArticleCancer cell international2026
Single-cell and bulk omics uncover fibroblast heterogeneity and HSPH1 as a key driver in Barrett's esophagus to esophageal adenocarcinoma progression.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundEsophageal adenocarcinoma (EAC) is a highly aggressive malignancy with poor prognosis, often evolving from Barrett's esophagus (BE). Understanding the molecular mechanisms driving this progression is critical for identifying diagnostic biomarkers and therapeutic targets.
methodsWe integrated single-cell RNA sequencing and bulk transcriptomic datasets to investigate fibroblast heterogeneity and epithelial-stromal crosstalk across disease stages. A disease-associated fibroblast signature (DAFS) was established and applied for consensus clustering to define EAC molecular subtypes. HSPH1, the core prognostic gene, was identified using multiple machine learning algorithms and further analyzed for pathway enrichment, immune landscape, and drug sensitivity. Its expression and function were subsequently validated by immunohistochemistry and in vitro assays.
resultsDistinct fibroblast subpopulations were identified in BE and EAC, with specific clusters exhibiting enhanced interactions with epithelial cells. Ligand-receptor analysis revealed key signaling pathways, including COL1A1-SDC1, MDK-NCL, and ITGA2-ITGB1, potentially contributing to malignant transition. Molecular subtyping revealed two EAC clusters with distinct immune infiltration. Among the DAFS genes, HSPH1 was identified as a key prognostic marker associated with higher tumor mutation burden, reduced immune infiltration, and increased tumor purity. Functional assays confirmed that HSPH1 promotes EAC cell proliferation, migration, and invasion. A progressive increase in HSPH1 expression from normal tissue to BE to EAC supports its potential utility as a biomarker for malignant progression.
conclusionOur study reveals critical fibroblast-epithelial interactions in NC-BE-EAC progression and identifies HSPH1 as a potential biomarker and therapeutic target. These findings may facilitate risk stratification and personalized treatment strategies for EAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.